Photo of Neil Lagali

Neil Lagali


Professor in experimental ophthalmology.

Cornea research for understanding the pathogenesis of disease

In our research group, we investigate mechanisms leading to blinding pathologies of the cornea at the molecular, gene- and tissue level.

We also use the cornea as an experimental model to gain insights into neovascular disease (angiogenesis). New regenerative treatments and surgical techniques are being researched and developed, and patient populations are being characterized in clinical studies using advanced imaging techniques. Some of the ongoing projects in the group include:

  • Mechanisms and treatment of corneal neovascularization
  • Non-invasive imaging of peripheral nerve fibers in the cornea as a surrogate marker for diabetes onset and progression
  • Clinical, molecular and genetic studies of European aniridia cohorts
  • Bioengineering the cornea: from materials to clinical applications

Developing new therapies for blindness and visual impairment

Our research group has a strong focus on developing new surgical methods and evaluating experimental compounds and drug delivery methods for treating corneal disease.

For over a decade the Lagali lab has been experimenting with femtosecond laser-based corneal surgery to evaluate the wound healing response and develop less invasive surgical methods. Wound healing, inflammation, and neovascularization can be triggered by surgery, and the goal is to minimize these unwanted effects by adapting the surgery to cause minimal trauma to the cornea.

Collaborating with adjunct Senior Lecturer Mehrdad Rafat from the Department of Biomedical Engineering, surgeries are being developed for implantation of bioengineered materials to enable vision restoration and long-term delivery of drugs to the cornea.

Picture of person having their eye examined in a machine.Femtosecond laser interface used for cutting and reshaping the cornea. Photo credit Thor Balkhed

EU COST Action CA18116 – Aniridia: networking to address an unmet medical, scientific, and societal challenge (ANIRIDIA-NET), 2019 – 2023

Action Coordinator and Main Proposer: Neil Lagali

Aniridia is a devastating ocular disease requiring intensive eye care, social and community support from birth and throughout an individual's lifetime. A congenital genetic mutation causes an underdeveloped retina, cataract, glaucoma, and a progressive ocular surface disease of stem cell deficiency and loss of corneal transparency. Classified as a rare disease (ORPHA:77), aniridia is extremely challenging for the ophthalmologist, with very few effective treatments available. This stems from a lack of adequate-sized patient populations to conduct coordinated clinical and research activities, and a lack of information exchange in assessing and treating aniridia, with expertise typically limited to geographically-dispersed centers. The goals of ANIRIDIA-NET are therefore to:

  1. Build a large, inclusive EU network of ophthalmologists, scientists, trainees, aniridia patient organizations, industry, and special interest groups to create linkages and a rich training ground for a new generation of trainees;
  2. Improve aniridia management through evidence-based research, harmonized clinical protocols, pooling/sharing of samples and models, and consensus activities; and
  3. Stimulate development of novel diagnostics and treatments for aniridia based on innovative research in regenerative medicine/stem cells, investigational drugs, gene therapy, tissue engineering, transplantation, etc.


Although a rare disease, aniridia is associated with ocular surface pathology such as dry eye, inflammation, stem cell insufficiency, nerve degeneration, and vascularization - problems common to many ocular surface pathologies collectively affecting large populations. Greater collaboration and sharing of information and resources in the area of aniridia is therefore additionally expected to have significant benefits for the treatment of larger patient populations with ocular surface disease.


EU Horizon2020 RIA Project: Advanced Regenerative and Restorative Therapies to Combat Corneal Blindness (ARREST BLINDNESS), 2016 – 2020

Project Coordinator: Neil Lagali

ARREST BLINDNESS is a consortium of 13 institutions in 8 countires, performing a four-year research project funded by the HORIZON 2020 program of the European Commission. Within the project we are developing and validating advanced regenerative and restorative therapies to treat the loss of corneal transparancy so that it does not result in blindness.

Read more:


The world's largest eye research organization praises LiU researchers

Neil Lagali and Mehrdad Rafat earn global acclaim, winning ARVO Foundation's 2023 Point of View Award. Recognized by the world's largest eye research organization, their work in regenerative ophthalmology offers new hope for vision restoration.

Eleni Stavrinidou.

Researchers receive large funding grants

Under Horizon 2020, the EU’s framework programme for research and innovation, nearly SEK 800 billion was awarded to researchers. At Linköping University, 117 projects received funding – grants that have made several research breakthroughs possible.

Close-up of an eye.

European investment in research into corneal diseases

Researchers at Linköping University are taking part in the largest European investment to date into diseases of the cornea. The aim is to restore vision in people with severe and rare eye diseases.

In the media




Video recorded in connection with the professor installation at LiU on September 4, 2021.



Aniridia awareness video from @AniridiaNet #CA18116 action in cooperation with @AniridiaEurope



Aniridia Europe Webinar - Interview to Prof. Neil Lagali and Prof. Claus Cursiefen


Joining Forces in Corneal Regeneration Research, project time 2013-2017.

Podcasts I participated in:

News items